Important Notice - Better Health, Brighter Future · 2007 2008 2009 2010 2011 2012 2013 2014 2015. FY2016 and Future Outlook 16 140th Ordinary General Meeting of Shareholders

June 29, 2016

140th Ordinary General Meeting of ShareholdersReports on the Business Report, Consolidated Financial Statements and Unconsolidated Financial Statements for the 139th Fiscal Year

Christophe WeberPresident & Chief Executive Officer

140th Ordinary General Meeting of Shareholders | June 29, 20161

Important Notice

Forward-Looking Statements

This presentation contains forward-looking statements regarding Takeda’s future business, financial position and results of operations, including estimates, forecasts, targets and plans. These forward-looking statements may be identified by the use of forward-looking words such as “aim,” “anticipate,” “assume,” “believe,” “continue,” “endeavor,” “estimate,” “expect,” “forecast,” “initiative,” “intend,” “may,” “outlook,” “plan,” “potential,” “probability,” “pro-forma,” “project,” “risk,” “seek,” “should,” “strive,” “target,” “will” or similar words, or expressions of the negative thereof, or by discussions of strategy, plans or intentions.

Any forward-looking statements in this document are based on the current assumptions and beliefs of Takeda in light of the information currently available to it. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takeda’s business, including general economic conditions in Japan, the United States and worldwide; competitive pressures and developments; applicable laws and regulations; the success or failure of product development programs; decisions of regulatory authorities and the timing thereof; changes in exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; and post-merger integration with acquired companies, any of which may cause Takeda’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by suchforward-looking statements. Neither Takeda nor its management gives any assurances that the expectations expressed in these forward-looking statements will turn out to be correct, and actual results, performance or achievements could materially differ from expectations.

Any forward looking statements herein speak only as of the date of this document, and Takeda and its management undertake no obligation to update or revise any forward-looking statements or other information contained in this presentation, whether asa result of new information, future events or otherwise.

Medical Information

This presentation contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drug including the ones under development.


Business Environment Surrounding Takeda

2 140th Ordinary General Meeting of Shareholders | June 29, 2016

Number of FDA Drug Approvals is Increasing Driven by New Scientific Insight

Novel approvals in the U.S.A.*

x245

41

27

39

30

212524

1822

20152006

* Approved by CDER (Center for Drug Evaluation and Research) and CBER (Center for Biological Evaluation and Research) in the U.S.A.

From website: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/ucm373420.htm


Truly Differentiated Medicines are Increasingly Sourced from Biotechs and Academia

27%

54%

73%

46%

20152007

Source: EvaluatePharma®

Origination of Global Top 100 Productsby Worldwide Sales

Pharma

Biotech, Non-profit,Academia

Pharma

Biotech,Non-profit,Academia


Takeda's Strategic Roadmap: Focus on Execution


6

Takeda Strategic RoadmapOn the Road to Sustained Growth

- Takeda-ismPatient → Trust → Reputation → Business

- Patient and customer centricity- Agile global organization- Fostering talent

- Focused world class R&DNew approaches to innovation

- Sustaining sales growthGI, Oncology, CNS and Emerging Markets

- Sustaining profit growthCost discipline

VALUES

PEOPLE

R&D

BUSINESSPERFORMANCE

Strategy


7

VALUES Corporate Philosophy


Takeda-ism will guide us to reach our Vision

We take action and make decisions by focusing on our four priorities, in order of:

Putting the patientat the center1 2 3 4Building trust

with societyReinforcing ourreputation

Developing thebusiness

We serve the needs of our patients, wherever they are. We earn the trust of society and customers through Takeda-ism. We are recognized as best in class because of agility and innovation, qualities that help us build a steady pipeline and deliver growth, year on year.

Our mission is to strive towards Better Health and a Brighter Future for people worldwide through leading innovation in medicine

8

Actively Engaged in CSR to Promote a Sustainable SocietyVALUES

Our Key CSR & Access to Medicine Activitiesfor Patients & People

■ Global Measles Vaccination Program for 5 million Children

■ Maternal and Child Health Programs in 7 Asian countries

- Selected by global employees voting- Aligned with the UN Sustainable Development Goals

Improving Access to Medicines

Partnering Global

Programs

Employee Volunteer

Participation

Supporting Disaster Reliefin Tohoku & Kumamoto

Initiatives in FY2016


9

Global, Diverse and ExperiencedTakeda's Executive Team (TET)

Christophe WeberPresident & CEO

PresidentJapan PharmaBU

Masato Iwasaki

PresidentGlobal Oncology BU

Christophe Bianchi

PresidentUS BU

Ramona Sequeira

Corporate Communications and Public Affairs Officer

Haruhiko Hirate

Global General Counsel

Yoshihiro Nakagawa

Global Human Resources Officer

David Osborne

PresidentEmerging MarketsBU

Giles Platford

PresidentEUCAN BU

Marc Princen

PresidentGlobal Vaccine BU

Rajeev Venkayya

Corporate Strategy Officer

Shinji Honda

Chief Financial Officer

Global Quality Officer

Gerard Greco

Chief Medical and Scientific Officer

Andrew Plump

Global Manufacturing and Supply Officer

Thomas Wozniewski

James Kehoe

PEOPLE



FY2015 Annual Results


0.0

10.0

20.0

30.0

40.0

50.0

60.0

70.0

80.0

90.0

2014Jun.

2014Sep.

2014Dec.

2015Mar.

2015Jun.

2015Sep.

2015Dec.

2016Mar.

2016May

Emerging markets

Europe and Canada

U.S.

900

800

700

600

500

400

300

200

100

02014Jun.

2014Sep.

2014Dec.

2015Mar.

2015Jun.

2015Sep.

2015Dec.

2016Mar.

2016May

11

GI: ENTYVIO®

On Track to Exceed $2bn MAT Sales within FY2018

MAT*Revenue(oku-yen)


Approx. 47,000 patients treated

>580,000 vials manufactured

Approved in 50 countries

Emerging Markets

Europe &Canada

U.S.

Constant Currency

BUSINESSPERFORMANCE

* MAT: Moving Annual Total

0.0

1.0

2.0

3.0

4.0

5.0

6.0

7.0

8.0

2015Dec.

2016Jan.

2016Feb.

2016Mar.

2016Apr.

2016May.

U.S.

12

Oncology: NINLARO®

Encouraging Uptake in the US since Dec 2015 Launch

IISR: Investigator Initiated Sponsored Research


Revenue(oku-yen)

Cumulative Sales @ Constant Currency

70

60

50

40

30

20

10

02015Dec.

2016May

2016Feb.

2016Jan.

2016Mar.

2016Apr.

2,500 patients treated in US,94% market coverage achieved

Appealing and requesting a re-examination in EU

5 pivotal Ph-3;80 IISR studies approved and

ongoing

BUSINESSPERFORMANCE

13

Growth Drivers Continue to Boost Our Top line Growth

GI*

Oncology***

Emerging Markets*

+9.5%

+23.6%

+1.0%

+4.8%

FY14(oku-yen)

Growth Drivers Total**

52%Growth Drivers Total**

Takeda Total

Underlying revenue growth

FY15

CNS

2,977

3,364

3,314

569

2,409

3,330

3,163

415 +37.3%

(oku-yen)

* Sales of pantoprazole in Emerging Markets (EM) is included in EM, but not in GI (Gastrointestinal),as it is a key driver in EM. Sales of pantoprazole in other regions is not included in this slide.

** Total GI/Oncology/CNS/EM, eliminated duplications (e.g. ADCETRIS in EM and in Oncology)*** Underlying growth of Oncology excl. VELCADE royalties is +4.4%

Performance by Growth Driver


BUSINESSPERFORMANCE

14

Robust Growth Driven by the U.S.and Emerging Markets


FY15 Regional Revenue* vs. FY14

BUSINESSPERFORMANCE

+4.8%[+7.0%]

-0.3%[+3.0%]

* % in parenthesis represents growth of product sales, excluding royalty and other income.

+5.5%[+5.4%]

Underlying revenue growth

EmergingMarkets

+12.4%[+14.3%]

U.S.

Europe andCanada

-3.3%[-2.8%]

JapanPharma

Japan Consumer Health and Others


FY2015 Management Guidance Delivered; ROE is Improving

Fiscal Year

15.1

10.9

11.8

6.1

14.4

6.34.5

- 6.3

(%)

0

Historical Takeda's ROE

1.43.9

ExcludingActos settlement

BUSINESSPERFORMANCE

2007 2008 2009 2010 2011 2012 2013 2014 2015

FY2016 and Future Outlook



Our Long-term Aspiration

• We serve the needs of our patients, wherever they are.

• We earn the trust of society and customers through Takeda-ism.

• We are recognized as best in class because of agility and innovation, qualities that help us build a steady pipeline and deliver growth, year on year.

Vision 2025

o No.1 GIo Top 10 Oncologyo Strong CNS and EM Presence


VALUESR&D

Oncology

GI

CNS

Vaccines

Specialty CV

Other

Strengthening Our Pipeline is Key for Our Long-term Success

Phase 1 Phase 2 Phase 3 Life Cycle ManagementTAK-243UAE inhibitorSolid Tumors

TAK-580pan-RAF kinaseSolid Tumors

TAK-931CDC7 inhibitor Solid Tumors

TAK-202 CCR2 antagonist

Solid Tumors

TAK-659SYK inhibitor

Hematologic malignancies

ENTYVIO®

α4β7 mAbUC/CD (EM, JP), adalimumab H2H Subcutaneous formulation UC/CD

PSC, GvHD, IO Colitis

AMITIZA®

Chloride channel activatorPediatric constipation

New formulation

PevonedistatNAE inhibitor

HR MDS

TAK-117PI3Kα

NSCLC

TAK-228mTORC 1/2

RCC

alisertibAurora A kinase

SCLC

trebananib (JP) Anti-angiopoietin peptibody

Ovarian Cancer

NINLARO®

Proteasome inhibitor MM R/R (EU/EM), R/R AL Amyloidosis,

Front Line MM Maintenance MM post-SCT Maintenance MM w/o SCT

ADCETRIS®

CD30 ADC HL Post Transplant

FL HL, FL MTCL, Relapsed CTCL

DEXILANT®

PPIARD in adolescents

TAKECAB®

PCABARD (Asia)

PPI Partial Responder

TAK-828ROR t inverse agonist

Crohn’s Disease

TAK-041 GPR139 agonist

CIAS neg. symptoms

TAK-071M1PAM LBD-AD

TAK-0585-HT3 antagonist

CIAS

TAK-653AMPAR potentiator

TRD

TAK-831DAAO inhibitor

Schizophrenia, Ataxia

TAK-935CH24H inhibitor

Epilepsy

TAK-915PDE2Ai LBD-AD

TAK-063PDE10Ai

Schizophrenia

AD-4833 TOMM40Mitochondrial growth modulator

Delay of MCI

AZILECT®

MAOB inhibitor Parkinson’s (JP)

TRINTELLIXTM

Multimodal anti-depressantCognition data in label (CRL received)

MDD (JP), ADHD

TAK-003 Dengue

TAK-214 Norovirus

TAK-850 (JP) Influenza

TAK-021EV71

TAK-272 Direct renin inhibitor

Diabetic Nephropathy

AZILVA®

FDC w/ amlodipine & HCTZ (JP) ARB

Hypertension

NESINA®

FDC with Met (JP) DPP4i T2DM

AMG 403NGF Pain

TAK-079Anti-CD38 mAb

RA

TAK-020BTK inhibitor

RA

namilumabGM-CSF

Psoriasis & RA

ULORIC®

XAO inhibitor XR Formulation

Hyperuricemia

BENET ®

Bone resorption inhibitor

Additional formation (JP)

relugolix***(TAK-385)

LH-RH antagonist Prostate cancer

* XMT-1522 is still pre-clinical; IND expected in 2016 ** TAK-195 is still pre-clinical; Phase 1 start expected in Q4 FY2016*** Relugolix also in Phase 3 for uterine fibroids, Phase 2 for endometriosis. Takeda has granted Myovant an exclusive, worldwide license to relugolix, excluding Japan and certain

other Asian countries. See appendix for list of abbreviations

XMT-1522*anti-HER2 ADCSolid Tumors

TAK-195**sIPV

TD-8954 Selective 5-HT4 receptor agonistEnteral Feeding

Intolerance

18

19

Focusing Our Efforts in the Therapeutic Areas Where We Want to be at the Cutting Edge of Innovation

VALUESR&D

Oncology

Gastroenterology (GI)

Central Nervous System (CNS)

Specialty CV

Vaccines

Core focus

We are focusing our innovation in three core therapeutic areas where we have:• Track record of recent successes• Deep scientific expertise• High unmet patient need

We are committed to global public health through our Vaccines portfolio

Targeted approach to specific assets



External Partnership is KeyTakeda-CiRA Joint Program for iPS Cell Applications

20

VALUESR&D

Nature (May 26, 2016)

http://www.nature.com/advertorials/insideview/pdf/ivtakedamay2016.pdf


FY2016 Management Guidance and Mid-Term Milestones

Underlying Mid-Term (3 year) Milestones (CAGR*)

Revenue: Mid-single digit

Core Earnings: Double digit

* CAGR: Compound Annual Growth Rate

FY2016 Management Guidance (Growth %)

Revenue: Mid-single digit

Core Earnings: Low- to mid-teen

Core EPS: Low- to mid-teen

Annual Dividend per Share180 yen for FY2016

Proposal for a New Governance StructureFrom "A Company with Board of Corporate Auditors" to "A Company with Audit and Supervisory Committee"

22

Y. Hasegawa President & CEO

C. Weber

Corporate Strategy Officer

S. Honda

JPBU PresidentM. Iwasaki

Chief Medical & Scientific Officer

A. Plump

Y. YamanakaInternal director

S. Kuniya K. Hatsukawa J. L. Butel

F. Sudo M. Sakane Y. FujimoriT. Shiga E. HigashiM. Orsinger

Internal directors

External directors


Chairman

Audit & Supervisory Committee directors

23

Centuries of Takeda’s History and Outlook

1781 ~Founding –

Modernization

1944 ~Business

diversification

1993 ~Pharmaceutical Focus Overseas Expansion

2003 ~Globalization

Transforming into Global One Takeda


Better Health, Brighter Future

Thank-you


Documents

Important Notice - Better Health, Brighter Future · 2007 2008 2009 2010 2011 2012 2013 2014 2015. FY2016 and Future Outlook 16 140th Ordinary General Meeting of Shareholders